Skip to main content
SpringerLink
Log in

Pharmacological Treatment with the Selective Serotonin Reuptake Inhibitors

  • Chapter
  • First Online:
Panic Disorder

  • 1827 Accesses

Abstract

The selective serotonin reuptake inhibitors (SSRI) are considered drugs of first choice for the treatment of panic disorder (PD) due to their clinical efficacy demonstrated by 11 randomized placebo-controlled trials and favorable side effects profile. SSRI’s mechanism of action in PD treatment still not completely understood, but the role of serotonin in the pathophysiology of this disorder has been studied for the last few years by neuroimaging, neurochemical and challenge studies. In this chapter, efficacy studies, common side effects and drug interactions of the SSRI are described as well as general recommendations for their clinical use in PD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Andrisano C, Chiesa A, Serretti A. Newer antidepressants and panic disorder: a meta-analysis. Int Clin Psychopharmacol. 2013;28:33–45.

    Article  PubMed  Google Scholar 

  2. Batelaan NM, Van Balkom AJLM, Stein DJ. Evidence-based pharmacotherapy of panic disorder: an update. Int J Neuropsychopharmacol. 2012;15:403–15.

    Article  CAS  PubMed  Google Scholar 

  3. Schmidt NB, Keogh ME. Treatment of panic. Annu Rev Clin Psychol. 2010;6:241–56.

    Article  PubMed  Google Scholar 

  4. Furukawa TA, Watanabe N, Churchill R. Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database Syst Rev. 2007;1:CD004364.

    PubMed  Google Scholar 

  5. Watanabe N, Churchill R, Furukawa TA. Combination of psychotherapy and benzodiazepines versus either therapy alone for panic disorder: a systematic review. BMC Psychiatry. 2007;7:18.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403–39.

    Article  PubMed  Google Scholar 

  7. Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14 Suppl 1:S1.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Bakker A, van Balkom AJ, Spinhoven P. SSRI vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand. 2002;106(3):163–7.

    Article  CAS  PubMed  Google Scholar 

  9. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998;51:215–35.

    Article  CAS  PubMed  Google Scholar 

  10. Maron E, Shlik J. Serotonin function in panic disorder: important, but why? Neuropsychopharmacology. 2006;31:1–11.

    Article  CAS  PubMed  Google Scholar 

  11. Kennett GA, Lightowler S, de Biasi V, et al. Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function. Neuropharmacology. 1994;33(12):1581–8.

    Article  CAS  PubMed  Google Scholar 

  12. Yamauchi M, Tatebayashi T, Nagase K, Kojima M, Imanishi T. Chronic treatment with fluvoxamine desensitizes 5-HT2C receptor-mediated hypolocomotion in rats. Pharmacol Biochem Behav. 2004;78(4):683–9.

    Article  CAS  PubMed  Google Scholar 

  13. Gorman JM, Kent JM, Sullivan GM, Coplan JM. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry. 2000;157(4):493–505.

    Article  CAS  PubMed  Google Scholar 

  14. Lai CH, Wu YT, Yu PL, Yuan W. Improvements in white matter micro-structural integrity of right uncinate fasciculus and left fronto-occipital fasciculus of remitted first-episode medication-naïve panic disorder patients. J Affect Disord. 2013;150(2):330–6.

    Article  PubMed  Google Scholar 

  15. Lai CH, Wu YT. Changes in gray matter volume of remitted first-episode, drug-naïve, panic disorder patients after 6-week antidepressant therapy. J Psychiatr Res. 2013;47(1):122–7.

    Article  PubMed  Google Scholar 

  16. Miller HE, Deakin JF, Anderson IM. Effect of acute tryptophan depletion on CO2-induced anxiety in patients with panic disorder and normal volunteers. Br J Psychiatry. 2000;176:182–8.

    Article  CAS  PubMed  Google Scholar 

  17. Bertani A, Perna G, Arancio C, Caldirola D, Bellodi L. Pharmacologic effect of imipramine, paroxetine, and sertraline on 35 % carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study. J Clin Psychopharmacol. 1997;17:97–101.

    Article  CAS  PubMed  Google Scholar 

  18. Bell C, Forshall S, Adrover M, Nash J, Hood S, Argyropoulos S, et al. Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J Psychopharmacol. 2002;16:5–14.

    Article  CAS  PubMed  Google Scholar 

  19. Gorman JM, Liebowitz MR, Fyer AJ, Goetz D, Campeas RB, Fyer MR, et al. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol. 1987;7(5):329–32.

    Article  CAS  PubMed  Google Scholar 

  20. Schneier FR, Liebowitz MR, Davies SO, Fairbanks J, Hollander E, Campeas R, et al. Fluoxetine in panic disorder. J Clin Psychopharmacol. 1991;10(2):119–21.

    Article  Google Scholar 

  21. Michelson D, Lydiard RB, Pollack MH, et al. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. Am J Psychiatry. 1998;155:1570–7.

    Article  CAS  PubMed  Google Scholar 

  22. Michelson D, Allgulander C, Dantendorfer K, Knezevic A, Maierhofer D, Micev V, et al. Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. Br J Psychiatry. 2001;179:514–8.

    Article  CAS  PubMed  Google Scholar 

  23. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry. 1998;155:36–42.

    Article  CAS  PubMed  Google Scholar 

  24. Lecrubier Y, Bakker A, Dunbar G, Judge R; the Collaborative Paroxetine Panic Study Investigators. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr Scand. 1997; 95: 145–52.

    Google Scholar 

  25. Pollack M, Mangano R, Entsuah R, Tzanis E, Simon NM. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl). 2007;194:233–42.

    Article  CAS  Google Scholar 

  26. Sheehan DV, Burnham DB, Iyengar MK, Perera P. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry. 2005;66:34–40.

    Article  CAS  PubMed  Google Scholar 

  27. Londborg PD, Wolkow R, Smith WT, et al. Sertraline in the treatment of panic disorder: a multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry. 1998;173(7):54–60.

    Article  CAS  PubMed  Google Scholar 

  28. Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry. 1998;55:1010–6.

    Article  CAS  PubMed  Google Scholar 

  29. Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry. 1998;155:1189–95.

    Article  CAS  PubMed  Google Scholar 

  30. Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a double blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2003;64:1322–7.

    Article  CAS  PubMed  Google Scholar 

  31. Nair NPV, Bakish D, Saxena B, Amin M, Schwartz G, West TEG. Comparison of fluvoxamine, imipramine and placebo in the treatment of outpatients with panic disorder. Anxiety. 1996;2:192–8.

    Article  CAS  PubMed  Google Scholar 

  32. Asnis GM, Hameedia FA, Goddardb AW, Potkin SG, Black D, Jameel M, et al. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res. 2001;103:1–14.

    Article  CAS  PubMed  Google Scholar 

  33. Bandelow B, Behnke K, Lenoir S, Hendriks GJ, Alkin T, Goebel C, et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J Clin Psychiatry. 2004;65:405–13.

    Google Scholar 

  34. Lepola U, Arato M, Zhu Y, Austin C. Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. J Clin Psychiatry. 2003;64:654–62.

    Article  CAS  PubMed  Google Scholar 

  35. Mavissakalian MR. Imipramine vs. sertraline in panic disorder: 24-week treatment completers. Ann Clin Psychiatry. 2003;15:171–80.

    Article  PubMed  Google Scholar 

  36. Cavaljuga S, Licanin I, Kapic E, Potkonjak D. Clomipramine and fluoxetine effects in the treatment of panic disorder. Bosn J Basic Med Sci. 2003;3:27–31.

    PubMed  Google Scholar 

  37. Ribeiro L, Busnello JV, Kauer-Sant’Anna M, et al. Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res. 2001;34:1303–7.

    Article  CAS  PubMed  Google Scholar 

  38. Perna G, Bertani A, Caldirola D, et al. A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry. 2001;34:85–90.

    Article  CAS  PubMed  Google Scholar 

  39. Palatnik A, Frolov K, Fux M, Benjamin J. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol. 2001;21:335–9.

    Article  CAS  PubMed  Google Scholar 

  40. Baldwin DS, Birtwistle J. The side effect burden associated with drug treatment of panic disorder. J Clin Psychiatry. 1998;59 Suppl 8:39–44. discussion 45–6.

    CAS  PubMed  Google Scholar 

  41. Topiwala A, Chouliaras L, Ebmeier KP. Prescribing selective serotonin reuptake inhibitors in older age. Maturitas. 2014;77(2):118–23.

    Article  CAS  PubMed  Google Scholar 

  42. Kostev K, Rex J, Eith T, Heilmaier C. Which adverse effects influence the dropout rate in selective serotonin reuptake inhibitor (SSRI) treatment? Results for 50,824 patients. Ger Med Sci. 2014;12:Doc15.

  43. Demyttenaere K, Jaspers L. Review: Bupropion and SSRI-induced side effects. J Psychopharmacol. 2008;22(7):792–804.

    Article  CAS  PubMed  Google Scholar 

  44. Maina G, Albert U, Salvi V, Bogetto F. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry. 2004;65(10):1365–71.

    Article  CAS  PubMed  Google Scholar 

  45. Kimmel RJ, Seibert J. Is antidepressant-associated mania always an evidence of a bipolar spectrum disorder? A case report and review of the literature. Gen Hosp Psychiatry. 2013;35(5):577.

    Article  PubMed  Google Scholar 

  46. Mendhekar DN, Gupta D, Girotra V. Sertraline-induced hypomania: a genuine side-effect. Acta Psychiatr Scand. 2003;108(1):70–4.

    Article  CAS  PubMed  Google Scholar 

  47. Akiskal HS, Hantouche EG, Allilaire JF, Sechter D, Bourgeois ML, Azorin JM, et al. Validating antidepressant-associated hypo- mania (bipolar III): a systematic comparison with spontaneous hypomania (bipolar II). J Affect Disord. 2003;73(1–2):65–74.

    Article  PubMed  Google Scholar 

  48. Gordon M, Melvin G. Selective serotonin re-uptake inhibitors—a review of the side effects in adolescents. Aust Fam Physician. 2013;42(9):620–3.

    PubMed  Google Scholar 

  49. Mahendran R. The risk of suicidality with selective serotonin reuptake inhibitors. Ann Acad Med Singapore. 2006;35(2):96–9.

    PubMed  Google Scholar 

  50. Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ. 2009;180(3):291–7.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Chemali Z, Chahine LM, Fricchione G. The use of selective serotonin reuptake inhibitors in elderly patients. Harv Rev Psychiatry. 2009;17(4):242–53.

    Article  PubMed  Google Scholar 

  52. Schellander R, Donnerer J. Antidepressants: clinically relevant drug interactions to be considered. Pharmacology. 2010;86(4):203–15.

    Article  CAS  PubMed  Google Scholar 

  53. Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs. 2012;26(1):39–67.

    Article  CAS  PubMed  Google Scholar 

  54. Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008;30(7):1206–27.

    Article  CAS  PubMed  Google Scholar 

  55. Caraci F, Crupi R, Drago F, Spina E. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab. 2011;12(6):570–7.

    Article  CAS  PubMed  Google Scholar 

  56. Gillman PK. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. Headache. 2010;50(2):264–72.

    Article  PubMed  Google Scholar 

  57. Shapiro RE, Tepper SJ. The serotonin syndrome, triptans, and the potential for drug-drug interactions. Headache. 2007;47(2):266–9.

    Article  PubMed  Google Scholar 

  58. Evans RW, Tepper SJ, Shapiro RE, Sun-Edelstein C, Tietjen GE, Evans RW, et al. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache. 2010;50(6):1089–99.

    Article  PubMed  Google Scholar 

  59. Harvard Medical School. Antidepressants and tamoxifen. Drug interactions may increase risk of cancer recurrence or death. Harv Ment Health Lett. 2010;26(12):6–7.

    Google Scholar 

  60. Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry. 2009;70(12):1688–97.

    Article  CAS  PubMed  Google Scholar 

  61. Desmarais JE, Looper KJ. Managing menopausal symptoms and depression in tamoxifen users: implications of drug and medicinal interactions. Maturitas. 2010;67(4):296–308.

    Article  CAS  PubMed  Google Scholar 

  62. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. 2010;340(8):c693.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Carvalho AF, Hyphantis T, Sales PM, Soeiro-de-Souza MG, Macêdo DS, Cha DS, et al. Major depressive disorder in breast cancer: a critical systematic review of pharmacological and psychotherapeutic clinical trials. Cancer Treat Rev. 2014;40(3):349–55.

    Article  CAS  PubMed  Google Scholar 

  64. Hersh EV, Pinto A, Moore PA. Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clin Ther. 2007;29(Suppl):2477–97.

    Article  CAS  PubMed  Google Scholar 

  65. Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med. 2006;119(2):113–6.

    Article  CAS  PubMed  Google Scholar 

  66. Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(6):811–9.

    Article  CAS  PubMed  Google Scholar 

  67. Löppönen P, Tetri S, Juvela S, Huhtakangas J, Saloheimo P, Bode MK, et al. Association between warfarin combined with serotonin-modulating antidepressants and increased case fatality in primary intracerebral hemorrhage: a population-based study. J Neurosurg. 2014;120(6):1358–63.

    Article  PubMed  Google Scholar 

  68. Kharofa J, Sekar P, Haverbusch M, Moomaw C, Flaherty M, Kissela B, et al. Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke. 2007;38(11):3049–51.

    Article  CAS  PubMed  Google Scholar 

  69. Wallerstedt SM, Gleerup H, Sundström A, Stigendal L, Ny L. Risk of clinically relevant bleeding in warfarin-treated patients—influence of SSRI treatment. Pharmacoepidemiol Drug Saf. 2009;18(5):412–6.

    Article  CAS  PubMed  Google Scholar 

  70. Cochran KA, Cavallari LH, Shapiro NL, Bishop JR. Bleeding incidence with concomitant use of antidepressants and warfarin. Ther Drug Monit. 2011;33(4):433–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology. 2012;79:1862–65.

    Article  CAS  PubMed  Google Scholar 

  72. American Psychiatric Association. Practice guidelines for the treatment of patients with panic disorder. 2nd ed. Washington, DC: American Psychiatric Association; 2009.

    Google Scholar 

  73. Lejoyeux M, Adès J. Antidepressant discontinuation: a review of the literature. J Clin Psychiatry. 1997;58 Suppl 7:11–5. discussion 16.

    CAS  PubMed  Google Scholar 

  74. Judge R, Parry MG, Quail D, Jacobson JG. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol. 2002;17(5):217–25.

    Article  CAS  PubMed  Google Scholar 

  75. Andrews G. Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Aust N Z J Psychiatry. 2003;37:641–56.

    Article  Google Scholar 

  76. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ; WFSBP Task Force on Treatment Guidelines for Anxiety,Obsessive-Compulsive and Post-Traumatic Stress Disoders, et al. World Federation of Societies of Biological psychiatry (WFSBP) Guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders—first revision. World J Biol Psychiatry. 2008;9:248–312.

    Google Scholar 

  77. Canadian Psychiatric Association (CPA). Clinical practice guidelines management of anxiety disorders. Can J Psychiatry. 2006;51(Suppl):9–91.

    Google Scholar 

  78. Nardi AE, Freire RC, Mochcovitch MD, Amrein R, Levitan MN, King AL, et al. A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol. 2012;32(1):120–6.

    Article  CAS  PubMed  Google Scholar 

  79. Ballenger JC. Long-term pharmacologic treatment of panic disorder. J Clin Psychiatry. 1991;52(Suppl):18–23. discussion 24–5.

    PubMed  Google Scholar 

  80. Wright J, Clum GA, Roodman A, Febbraro GA. A bibliotherapy approach to relapse prevention in individuals with panic attacks. J Anxiety Disord. 2000;14:483–99.

    Article  CAS  PubMed  Google Scholar 

  81. Wiborg IM, Dahl AA. Does brief dynamic psychotherapy reduce the relapse rate of panic disorder? Arch Gen Psychiatry. 1996;53:689–94.

    Article  CAS  PubMed  Google Scholar 

  82. Nash MS, Willets JM, Billups B, John Challiss RA, Nahorski SR. Synaptic activity augments muscarinic acetylcholine receptor-stimulated inositol 1,4,5-trisphosphate production to facilitate Ca2+ release in hippocampal neurons. J Biol Chem. 2004;279(47):49036–44.

    Google Scholar 

  83. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000;61(11):863–7.

    Google Scholar 

  84. Montejo A, Majadas S, Rizvi SJ, Kennedy SH. The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Hum Psychopharmacol. 2011;26(8):537–42.

    Google Scholar 

  85. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006;80(1):61–74.

    Google Scholar 

  86. Bak S, Tsiropoulos I, Kjaersgaard JO, Andersen M, Mellerup E, Hallas J, et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke. 2002;33(6):1465–73.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Panic and Respiration, Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

    Marina Dyskant Mochcovitch & Tathiana Pires Baczynski

Authors
  1. Marina Dyskant Mochcovitch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tathiana Pires Baczynski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marina Dyskant Mochcovitch .

Editor information

Editors and Affiliations

  1. Laboratory of Panic and Respiration, Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

    Antonio Egidio Nardi

  2. Laboratory of Panic and Respiration, Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

    Rafael Christophe R. Freire

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Mochcovitch, M.D., Baczynski, T.P. (2016). Pharmacological Treatment with the Selective Serotonin Reuptake Inhibitors. In: Nardi, A., Freire, R. (eds) Panic Disorder. Springer, Cham. https://doi.org/10.1007/978-3-319-12538-1_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-12538-1_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-12537-4

  • Online ISBN: 978-3-319-12538-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation